Asia-Pacific Active Pharmaceutical Ingredient Market By Product (Amoxicillin, Cephalexin, Erythromycin, Fluoroquinolones), By Application(Infectious Disease, Oncology, Cardiovascular Disease), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2031

Increasing incidence and prevalence of numerous infectious diseases that are caused by microorganisms, such as bacteria, viruses, parasites, or fungi, which can spread directly or indirectly from one person to another are major factors expected to drive the growth of the Asia-Pacific active pharmaceutical ingredient market.

Market.US announces the publication of its most recently generated research report titled, “Asia-Pacific Active Pharmaceutical Ingredient Market by Product Type(Amoxicillin, Cephalexin, Erythromycin, Fluoroquinolones, Other Product Types), by Application(Infectious Disease, Oncology, Cardiovascular Disease, Other Applications), and by Countries – Asia-Pacific Forecast to 2030”, which offers a holistic view of the Asia-Pacific Active Pharmaceutical Ingredient Market through systematic segmentation that covers every aspect of the target market.

The Asia-Pacific Active Pharmaceutical Ingredient Market is projected to be US$ 7,781.1 Mn in 2021 to reach US$ 12,335.1 Mn by 2030 at a CAGR of 5.3%.

Active Pharmaceutical Ingredient (API) is also called bulk ingredients. API is the part of any drug that produces the desired effects on humans or animals. API substances are intended to furnish pharmacological activity or other direct effects in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure and function of the body.

All drugs are made up of two essential components, the API –the central ingredient and the excipient – the substances other than the drug that helps deliver the medication Excipients are generally chemically inactive substances, such as lactose or mineral oil in the tablet or pill.

The API form that is used in a drug formulation is often the most thermodynamically stable crystalline form. The quality of the API plays an important role in the quality of a drug product.

Asia-Pacific Active Pharmaceutical Ingredient Market Revenue (US$ Mn), 2021–2031

Source: Prudour, 2021

Rising number of cases of hospital-acquired infections such as bloodstream infection, pneumonia, urinary tract infection (UTI), surgical site infection, and others. This, among other factors expected to propel the growth of the Asia Pacific active pharmaceutical ingredient for the antibiotic market.

Increasing incidences and prevalence of oncology diseases, which is a broad-spectrum antibiotic for the treatment to fight bacterial infections. Antibiotics are used against leukemia, bladder cancer, testicular cancer, and sarcoma treatment. These are significant factors expected to boost the growth of the Asia Pacific active pharmaceutical ingredient for the antibiotic market.

The ongoing COVID-19 pandemic which has increased the usage of antibiotics to fight emerging antibiotic-resistant infections such as dangerous new coronavirus and SARS-CoV-2. This creates an opportunity for small and prominent players engaged in the manufacturing of active pharmaceutical ingredients for the antibiotic.

Higher penetration of fake medicine/ counterfeit medicine, which may be contaminated or contain the wrong or no active ingredient. This is a factor that may hamper the growth of the Asia Pacific active pharmaceutical ingredient for the antibiotic market to a certain extent.

Asia-Pacific Active Pharmaceutical Ingredient Market Attractiveness Analysis by Product Type, 2014–2030

Source: Prudour, 2021

The Asia Pacific active pharmaceutical ingredient for the antibiotic market is segmented based on product type, application, and regions. Based on product type, the market is segmented into Amoxicillin, Cephalexin, Erythromycin, Fluoroquinolones, Other Product Type. Based on end use, the Asia Pacific active pharmaceutical ingredient for the antibiotic market is segmented into infectious disease, oncology, cardiovascular disease.

Among the product segments, the amoxicillin segment is expected to register a relatively higher revenue growth over the forecast period. Among the application segments, the infectious disease segment is expected to register a relatively higher revenue growth over the forecast period.

Among the regions, revenue from the market in North America is expected to register a significant revenue as compared to markets in other regions over the forecast period.

The research report on the Asia-Pacific active pharmaceutical ingredient market includes profiles of some of the major companies such as Roche Holding, Pfizer Inc., GlaxoSmithKline Plc, Sanofi S.A., Bristol-Myers Squibb Company, Merck KGaA, C.H. BoehringerSohn AG & Co. KG (Boehringer Ingelheim International GmbH), Teva Pharmaceutical Industries Ltd, Sun Pharmaceuticals Industries Ltd., Jiangsu Hengrui Medicine Co., Ltd, Aurobindo Pharma, and WuXi AppTec, among others.

Segmentation for Asia Pacific Active Pharmaceutical Ingredient for Antibiotic Market, based on Product Type, Application, and Country:

Based on Product Type:

• Amoxicillin
• Cephalexin
• Erythromycin
• Fluoroquinolones
• Other Product Type

Based on Application:

• Infectious Disease
• Oncology
• Cardiovascular Disease
• Other Applications

Based on Key Players

• Roche Holding
• Pfizer Inc.
• GlaxoSmithKline Plc
• Sanofi S.A.
• Bristol-Myers Squibb Company
• Merck KGaA
• C.H. BoehringerSohn AG & Co. KG (Boehringer Ingelheim International GmbH)
• Teva Pharmaceutical Industries Ltd
• Sun Pharmaceuticals Industries Ltd.
• Jiangsu Hengrui Medicine Co. Ltd
• Aurobindo Pharma
• WuXi AppTec
• among others.

Based on Countries:

• China
• Japan
• South Korea
• India
• Southeast Asia
• Rest of Asia-Pacific

For the Asia-Pacific Active Pharmaceutical Ingredient Market research study, the following years have been considered to estimate the market size: